Lipids & Metabolic

Just 45 minutes of chatting with a second-year medical student could improve disease management among patients with chronic conditions like hypertension, diabetes and chronic obstructive pulmonary disease (COPD), according to research published in the November issue of the Journal of the American Osteopathic Association.

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

A diabetic mother saddled with medical debt from type 1 diabetes (T1D) treatments and complications is highlighting the rising costs of insulin and T1D care in the United States, Forbes reports.

VITAL and REDUCE-IT—both highly anticipated trials revolving around the cardiovascular benefits of fish oil products—delivered mixed results at this year’s AHA Scientific Sessions in Chicago, with one trial observing few heart benefits from omega-3s while the other saw a 25 percent reduction in major cardiovascular events with a purified eicosapentaenoic acid product.

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Up to a quarter of type 1 diabetes patients in England should have access to the Freestyle Libre, a flash glucose monitor that allows diabetics to check their blood sugar without the need for finger pricks. But a recent investigation by the BMJ has concluded that, in reality, just 3 to 5 percent of eligible patients have access to the potentially life-changing technology.

It’s not just what people eat—but when—that may influence their risk of developing prediabetes and high blood pressure, according to preliminary research scheduled to be presented Nov. 10 at the American Heart Association’s Scientific Sessions in Chicago.

A clinical and economic analysis of PCSK9 inhibitors in Canadian patients with atherosclerotic cardiovascular disease (ASCVD) is solidifying physician concerns that the lipid-lowering drugs might be too inaccessible—or too pricey—to benefit the average heart patient.

Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.

Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

Coronary artery calcium (CAC) scoring could be the key to determining which patients are most likely to benefit from statin therapy, according to a retrospective analysis published Nov. 5 in the Journal of the American College of Cardiology.